J2355 Oprelvekin injection
Also known as: oprelvekin, Neumega
Injection of oprelvekin. A recombinant interleukin-11 for thrombocytopenia prevention.
In Plain Language
platelet booster; low platelet prevention
Clinical Context
Used to prevent severe thrombocytopenia and reduce need for platelet transfusions following myelosuppressive chemotherapy.
RVU Information
CPT J2355 does not have a physician work RVU assigned by CMS. This is typical for supply, drug, and equipment codes — reimbursement is based on Average Sales Price (ASP), fee schedules, or payer contracts rather than the RVU system.
Billing & Documentation
J-codes represent drugs administered by a healthcare provider (not self-administered). Documentation must include the drug name, dosage, route of administration, and medical necessity. Most payers require the National Drug Code (NDC) on the claim. Bill the appropriate administration code (96365-96379) in addition to the drug code.
Specialties
Frequently Asked Questions
What is CPT code J2355?
CPT J2355 (Oprelvekin injection) is a J Codes (Drugs) code. Injection of oprelvekin. A recombinant interleukin-11 for thrombocytopenia prevention.
How is J2355 administered?
CPT J2355 is administered by a healthcare provider, typically via injection or infusion. Used to prevent severe thrombocytopenia and reduce need for platelet transfusions following myelosuppressive chemotherapy. It is used by Oncology, Hematology.
When is CPT J2355 used?
Used to prevent severe thrombocytopenia and reduce need for platelet transfusions following myelosuppressive chemotherapy.
Track This Code in RVU Edge
Log procedures, calculate wRVUs, and benchmark against MGMA data — all in one app.
CPT® is a registered trademark of the American Medical Association. Data sourced from CMS Physician Fee Schedule RVU26A. Descriptions, synonyms, and clinical context are original content by RVU Edge.